Introduction {#S1}
============

The von Hippel-Lindau (*VHL*) gene functions as a tumor suppressor. Inactivating germline *VHL* mutations predispose to renal cell carcinoma (RCC) of clear-cell type (ccRCC) ([@R31]), and somatic *VHL* mutations frequently occur in sporadic ccRCC ([@R14], [@R42]), where they are accompanied by loss of heterozygosity. The VHL protein (pVHL) functions as the substrate recognition subunit of an E3 ubiquitin ligase complex that targets, among others, hypoxia-inducible factor (HIF) α subunits for degradation ([@R10], [@R25], [@R38], [@R43], [@R55]). The levels of HIF-α subunits are regulated by pVHL in an oxygen-dependent manner ([@R38]). When oxygen abounds, HIF-α subunits are hydroxylated at specific prolyl residues creating high affinity binding sites for pVHL with resultant polyubiquitylation and degradation ([@R20], [@R21], [@R37], [@R62]). In contrast, when oxygen levels are low, HIF-α subunits remain unmodified, evade pVHL recognition, interact with HIF-β leading to the formation of heterodimeric transcription factors that translocate to the nucleus where they regulate transcription ([@R45]). Both HIF-1α and HIF-2α subunits interact with Hif-1β and are regulated by pVHL ([@R24]). When pVHL is disrupted, HIF-1α and HIF-2α regulation becomes uncoupled from oxygen levels, leading to constitutive expression of their target genes ([@R44]).

*Vhl* function has been extensively studied in both epithelial and mesenchymal tissues ([@R26]). Homozygous *Vhl* mutant embryos die in midgestation seemingly from abnormal placental vascularization ([@R15]). *Vhl* inactivation at embryonic day (E)10.5 using a tamoxifen inducible Cre results in liver necrosis and death around E15 ([@R17]). *Vhl* is essential for liver function, and *Vhl* disruption in adult hepatocytes results in premature death, typically within weeks ([@R16], [@R29], [@R47], [@R48], [@R51]). However, despite extensive studies ([@R7], [@R16], [@R17], [@R29], [@R47], [@R48], [@R49], [@R51]) how *Vhl* is important for liver function and survival is not known. In adult hepatocytes, *Vhl* loss results in increased erythropoietin production with consequent polycythemia ([@R48], [@R49]), glycogen accumulation ([@R47]) and the accumulation of neutral lipids ([@R16], [@R29], [@R48], [@R51]). However, none of these functions have been linked to the death of mice. In addition, liver biosynthetic function appears to be preserved ([@R48]). Recently, pVhl was shown to be required for β-oxidation of fatty acids, and this may explain the steatotic phenotype ([@R51]). However, liver steatosis *per se* is unlikely to cause death. In all adult models, variable penetrance and unpredictable survival have made unraveling the cause of death impossible.

Here, we acutely inactivated *Vhl* in hepatocytes with an adenovirus coding for Cre recombinase (Ad-Cre) and using a variety of *ex vivo* and *in vivo* approaches, we demonstrate that *Vhl* is required for mitochondrial respiration in hepatocytes *in vivo* and that *Vhl* loss blocks ketone and glucose production leading to hypoketonemia, hypoglycemia and death within days. As evidenced by simultaneous *Hif-1β* inactivation, the deleterious effects induced by *Vhl* loss are Hif-dependent. Constitutive Hif activation in hepatocytes blocked mitochondria from utilizing available oxygen indicating that no other pathway in the liver exists that can overcome a perceived state of hypoxia imposed by Hif. To our knowledge, this is the first report to show that Hif activation is sufficient to block mitochondrial respiration *in vivo*.

Results {#S2}
=======

Acute *Vhl* inactivation in the liver leads to hepatic steatosis, hyperlipidemia, and death {#S3}
-------------------------------------------------------------------------------------------

*Vhl* is essential for normal liver function and survival. Consistent with previous studies ([@R16], [@R29], [@R48], [@R51]), albumin-Cre; *Vhl^F/F^*mice develop liver steatosis and exhibit a shortened life span ([Figure 1](#F1){ref-type="fig"}). We were interested in understanding what function *Vhl* played in hepatocytes that was essential for survival, but the variability in life expectancy across individual mice made it impossible to establish with certainty the cause of death ([Figure 1B](#F1){ref-type="fig"}). Whereas some mice would succumb before 4 weeks of age, others survived past 10 weeks. Furthermore, when moribund mice were evaluated it was impossible to determine whether the abnormalities observed were the cause of illness or simply indicators of their moribund state.

We reasoned that abrupt *Vhl* disruption using Ad-Cre may result in an accelerated and more synchronous phenotype amenable to longitudinal studies and experimental dissection. Ad-Cre would not only result in acute loss of pVhl, but also induce a state of stress providing thereby a sensitized background for analysis. Tail vein injection of Ad-Cre resulted in efficient *Vhl^F^* allele recombination in the liver ([Figure 2A](#F2){ref-type="fig"}). By contrast, Ad-Cre had little effect on *Vhl^F^* in other organs ([Figure 2A](#F2){ref-type="fig"}, [Figure S1A](#SD1){ref-type="supplementary-material"}). Three days after Ad-Cre, approximately 70% of the *Vhl^F^* allele in liver extracts was recombined and considering that hepatocytes account for 70-80% of the liver, it was estimated that *Vhl* was inactivated in almost all targeted cells. *Vhl^F^* recombination was accompanied by a decrease in pVhl, which was undetectable 3 days after Ad-Cre ([Figure 2B](#F2){ref-type="fig"}). As expected, pVhl depletion activated Hif leading to the upregulation of both Hif-1α liver specific targets such as *Pdk1* ([@R49]) as well as Hif-2α targets such as *Vegf* ([@R50]) ([Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

Ad-Cre mediated *Vhl* inactivation was lethal within days. Median survival of Ad-Cre *Vhl^F/F^* mice was 6 days and all mice were dead by day 10 ([Figure 2C](#F2){ref-type="fig"}). By contrast, survival was unaffected in similarly Ad-Cre injected *Vhl*^+/+^ animals. The differences between *Vhl^F/F^* and *Vhl*^+/+^ mice could not be attributed to differences in Ad-Cre as both strains showed similar changes in liver function tests and weight (data not shown). In addition, both *Vhl^F/F^* and *Vhl*^+/+^ livers exhibited a similar infiltration of immune cells ([Figure S1B](#SD1){ref-type="supplementary-material"}). The immune cell infiltration was manifested in *Vhl^F/F^* livers also by an increase in unrecombined *Vhl* allele starting at day 4 after Ad-Cre injection ([Figure 2A](#F2){ref-type="fig"}, [Figure S1A](#SD1){ref-type="supplementary-material"}). While the rapidity of the death may be exacerbated by the adenoviral infection, the death phenotype was clearly *Vhl*-dependent and none of the wild-type mice died ([Figure 2C](#F2){ref-type="fig"}). The brisk and nearly synchronous death of *Vhl^F/F^* mice provided a suitable experimental system to dissect the reason why *Vhl* function was essential for liver function and survival. In addition, by comparing to similarly Ad-Cre injected mice, we were able to exclude confounding effects from Ad-Cre.

This experimental paradigm allowed us to study the changes induced by *Vhl* loss longitudinally over time and obtain measurements before the mice became moribund. At day 3 post-Ad-Cre injection, both *Vhl^F/F^* and wild-type livers exhibited mild microsteatosis ([Figure S1B](#SD1){ref-type="supplementary-material"}). However, whereas the steatosis improved in wild-type animals, it worsened in *Vhl^F/F^* ([Figure 3A and B](#F3){ref-type="fig"}, [Figure S1B](#SD1){ref-type="supplementary-material"}). Oil red O staining indicated the accumulation of neutral lipids in *Vhl*-deficient livers ([Figure 3B](#F3){ref-type="fig"}, [Figure S1B](#SD1){ref-type="supplementary-material"}). Triglycerides were increased in Ad-Cre *Vhl^F/F^* livers ([Figure 3C](#F3){ref-type="fig"}) and the mice developed hypertriglyceridemia ([Figure 3D](#F3){ref-type="fig"}). By contrast, liver cholesterol content was comparable in all animals ([Figure 3E](#F3){ref-type="fig"}), and circulating cholesterol was only mildly elevated in Ad-Cre *Vhl^F/F^* mice ([Figure 3F](#F3){ref-type="fig"}).

As fasting may cause mild liver steatosis and to adjust for potential differences in food intake between Ad-Cre injected *Vhl^F/F^* and *Vhl*^+/+^ mice, similar studies were performed after a 24 hour fast. While fasting resulted in an increase in baseline TG in the liver and to some extent in the plasma, higher TG levels were again observed in *Vhl^F/F^* mice ([Figure 3C and D](#F3){ref-type="fig"}).

Interestingly, the lipid accumulation in *Vhl*-deficient livers was reminiscent of ccRCC which accumulate neutral lipids giving raise to the clear-cell histological appearance ([Figure 3G](#F3){ref-type="fig"}). However, while cholesterol esters are known to be increased in ccRCC ([@R13], [@R58]), whether TG accumulate is less clear. We analyzed the lipid composition of a set of ccRCCs and compared the results to samples of normal renal cortex, from where ccRCCs are thought to arise ([@R63]). Our data show that ccRCCs accumulate not only cholesterol but, like hepatocytes, also TG ([Figure 3H](#F3){ref-type="fig"}).

The rapid accumulation of TG in the liver of Ad-Cre *Vhl^F/F^* mice suggested that the role of pVhl in survival may be linked to its role in lipid metabolism. To obtain insight into the metabolic abnormalities underlying the steatosis phenotype, we performed extensive gene expression studies of ∼40 genes implicated in lipid metabolism ([Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). In addition, we also directly measured the production by the liver of key metabolites by performing *ex vivo* liver perfusion experiments. qRT-PCR studies were performed in *Vhl^F/F^* and *Vhl*^+/+^ livers on days 3 and 4 following Ad-Cre injection. The cyclophilin gene (*Ppib*) was chosen for normalization because, unlike other housekeeping or cytoskeletal genes, its expression was not altered by Ad-Cre (data not shown). In uninjected *Vhl^F/F^* and *Vhl*^+/+^ livers gene expression was, as expected, very similar (Day 0, [Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). However, marked differences were observed between *Vhl^F/F^* and *Vhl*^+/+^ livers following Ad-Cre ([Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Hif target genes, including the recently described *Insig-2a* ([@R41]), were induced up to 13 fold in *Vhl*-deficient livers ([Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Among the genes that were markedly upregulated following *Vhl* disruption was the VLDL receptor ([Table 1](#T1){ref-type="table"}), which has been recently proposed to be regulated by Hif-1 ([@R27], [@R34]). In addition, SREBP-1c, an important activator of fatty acid (FA) synthesis genes ([@R18]), was downregulated over 20-fold in *Vhl*-deficient livers ([Table 1](#T1){ref-type="table"}). By contrast, the expression of PPARγ was not significantly altered ([Table 1](#T1){ref-type="table"}). With respect to genes involved in triglyceride synthesis there was no uniform trend; while the mRNAs for acyl glycerol-3-phosphate acyltransferase 3 and 4 were modestly increased, expression of diacylglycerol acyltransferase 2 was decreased, and the expression of several other genes was unchanged ([Table 1](#T1){ref-type="table"}). Overall the data suggested that the accumulation of TG in the liver was not due to increased lipogenic gene expression.

Inhibition of ketone production in *Vhl*-deficient livers {#S4}
---------------------------------------------------------

To evaluate the cause of death, we measured plasma ketone levels, a key energy source for peripheral tissues during fasting ([@R59]). As expected in uninjected, fasted, *Vhl^F/F^* and *Vhl*^+/+^ mice, plasma ketone levels were indistinguishable ([Figure 4A](#F4){ref-type="fig"}, day 0). Following Ad-Cre injection, circulating ketone levels remained constant in *Vhl*^+/+^ mice, but dropped significantly in *Vhl^F/F^* mice ([Figure 4A](#F4){ref-type="fig"}). As early as day 3 post Ad-Cre, circulating ketones were almost 2-fold lower in *Vhl^F/F^* compared to *Vhl*^+/+^ mice and the levels progressively decreased over time ([Figure 4A](#F4){ref-type="fig"}). Next, we evaluated ketone body production in *ex vivo* perfusion experiments of intact livers. The levels of ketone bodies produced by *Vhl*-deficient livers were substantially lower than those produced by wild-type livers ([Figure 4B](#F4){ref-type="fig"}). These data indicated that disruption of pVhl resulted in an inhibition of liver ketogenesis markedly reducing the amounts of circulating ketone bodies.

Low ketone production was not caused by decreased expression of the rate limiting enzyme, 3-hydroxy-3-methylglutaryl-CoA synthase 2 ([Table 2](#T2){ref-type="table"}). However, we observed a 2-fold decrease in FAO rates in liver homogenates from *Vhl^F/F^* animals as early as day 3 post Ad-Cre injection ([Figure 4C](#F4){ref-type="fig"}). In addition, the expression of several PPARα target genes was downregulated even when PPARα itself was not ([Table 2](#T2){ref-type="table"}). Notably, PPARα activity has been shown to be downregulated by HIF-1α ([@R1], [@R19]) and the phenotype observed was reminiscent of fasted PPARα-deficient mice ([@R35]). Thus, we sought to activate PPARα in *Vhl^F/F^* mice and used a pharmacological activator, WY-14643. As determined by the expression of PPARα target genes such as *Cyp4a14* and *Lcad*, WY-14643 led to PPARα activation in the livers of both wild-type and *Vhl^F/F^* Ad-Cre injected mice ([Figure 4D](#F4){ref-type="fig"}). However, despite PPARα activation and increased expression of lipolytic genes, WY-14643 did not seemingly affect liver steatosis or prolong the survival *Vhl^F/F^* mice ([Figure 4E](#F4){ref-type="fig"} and data not shown). Incidentally, during the experiments with WY-14643, we noted that in contrast to wild-type mice, the administration of either WY-14643 or olive oil (vehicle) to *Vhl^F/F^* animals caused the plasma to appear turbid and this was accompanied by a trend towards marked hypertrygliceridemia ([Figure 4F](#F4){ref-type="fig"}).

Decreased liver gluconeogenesis contributes to the death of *Vhl^F/F^* animals {#S5}
------------------------------------------------------------------------------

Next we evaluated glucose levels. At day 5 following Ad-Cre, glucose levels were significantly lower in *Vhl^F/F^* than in wild-type mice ([Figure 5A](#F5){ref-type="fig"}). However, whereas differences in circulating ketones were observed already at day 3, differences in glucose levels were not observed prior to day 5. Nevertheless, already at day 4, very profound differences were observed in liver glucogeneogenesis. As determined by *ex vivo* liver perfusion experiments, *Vhl*-deficient livers produced 70% less glucose than livers from wild-type mice ([Figure 5B](#F5){ref-type="fig"}). These findings were accompanied by a trend towards decreased expression of the major gluconeogenic regulator, peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (Pepck) ([Table 2](#T2){ref-type="table"}).

Overall, a profound disruption was observed in both glucose and ketone production by *Vhl*-deficient livers. To determine whether this represented a general disruption of liver metabolic functions, we measured urea production in perfused livers. Despite impaired gluconeogenesis and ketogenesis, urea production was not significantly different between *Vhl*-deficient and wild-type livers ([Figure 5C](#F5){ref-type="fig"}). Thus, the defects observed in glucose and ketone production were not the consequence of an overall impairment of liver function. Because ureagenesis requires mitochondria, the data also indicated that the alterations observed were not due to a global impairment of mitochondria.

Next, we sought to determine whether glucose supplementation would prolong the survival of *Vhl^F/F^* mice. For these experiments, *Vhl^F/F^* mice were given intraperitoneal glucose every 8 hours starting 70 hours after Ad-Cre injection. By comparison to saline treated *Vhl^F/F^* mice, the administration of glucose resulted in a modest, but statistically significant improvement in median survival (*p* = 0.025) ([Figure 5D](#F5){ref-type="fig"}). Taken together these data show that pVhl loss results in an inhibition of liver gluconeogenesis and that low glucose levels contribute to the death of the mice.

Inhibition of mitochondrial respiration by pVhl disruption {#S6}
----------------------------------------------------------

To analyze the liver metabolic phenotype further, we measured acylcarnitine levels. Free carnitine levels were lower in *Vhl*-deficient livers compared to wild-type in both fed and fasted states ([Figure 6A](#F6){ref-type="fig"}, [Table S1](#SD1){ref-type="supplementary-material"}). Lower free carnitine levels in *Vhl*-deficient livers correlated with an accumulation of short and medium chain acylcarnitines with an even number of carbon residues. Acetyl (C2) and butyryl (C4) carnitines were 2-3 fold increased in pVhl-depleted livers. In addition, under fasting conditions octanoylcarnitine (C8) was similarly increased in pVhl-depleted livers ([Figure 6A](#F6){ref-type="fig"}). These data indicated that *Vhl*-deficient livers failed to completely oxidize fatty acids.

To further evaluate the impairment in mitochondrial oxidative capacity, we measured oxygen consumption in intact livers. By comparison to wild-type livers from similarly Ad-Cre injected mice, oxygen consumption was reduced in *Vhl*-deficient livers. *Vhl*-deficient livers exhibited an approximately 2-fold decrease in oxygen extraction ([Figure 6B](#F6){ref-type="fig"}). Because mitochondria account for more than 90% of the oxygen consumed by tissues ([@R56]), these data indicated that pVhl disruption led to a striking suppression of mitochondrial respiration. Multiple factors are likely to contribute to the decreased mitochondrial respiration in *Vhl*-deficient livers. Hif-1 regulates pyruvate dehydogenase kinase (Pdk1) ([@R28], [@R46]) and *Pdk1* expression was elevated in *Vhl*-deficient livers 4-6 fold ([Table 2](#T2){ref-type="table"}). In addition, the Fe-S cluster assembly proteins IscU1/2 were recently shown to be regulated by pVhl ([@R6]) and IscU1/2 levels were reduced in the livers from Ad-Cre injected *Vhl^F/F^* mice ([Figure 6C and D](#F6){ref-type="fig"}).

We sought to extend our observations in perfused livers to live mice and measured pO~2~ in the liver of anesthetized animals using fluorine (^19^F) magnetic resonance imaging (MRI). For these experiments, Oxypherol, an MRI pO~2~ reporter probe that is sequestered in the liver, was administered to Ad-Cre injected *Vhl^F/F^* and *Vhl*^+/+^ mice and the mice were evaluated by ^19^F MRI. pO~2~ maps were acquired and overlaid onto T~1~-weighted ^1^H MRI anatomical images ([Figure 6E](#F6){ref-type="fig"}). Pronounced pO~2~ differences were observed between wild-type and *Vhl*-deficient livers. Whereas in wild-type livers hepatic pO~2~ was 31±14 torr, in *Vhl*-deficient livers pO~2~ was 83±24 torr (*p* \< 0.05; [Figure 6F](#F6){ref-type="fig"}). Thus, the 2-fold decrease in oxygen consumption in perfused *Vhl*-deficient livers previously observed correlated with a reciprocal increase of a similar magnitude in oxygen tension. Further experiments were performed with the administration of 100% O~2~. Increasing the inspired O~2~ concentration resulted in a similar fold increase in pO~2~ in both wild-type and *Vhl*-deficient livers ([Figure 6F](#F6){ref-type="fig"}). Thus, the delivery of oxygen to *Vhl*-deficient livers was intact. In summary, acute pVhl disruption resulted in a profound suppression of mitochondrial respiration and this is accompanied by a corresponding increase in pO~2~.

Rescue of Ad-Cre *Vhl^F/F^* mice by Hif-1β disruption {#S7}
-----------------------------------------------------

Finally, we sought to determine whether the phenotype observed was dependent on Hif. Because both Hif-1α and Hif-2α have been implicated in liver steatosis ([@R29], [@R51]), we chose to inactivate both of them by eliminating the shared Hif-1β subunit ([@R57]). Mice carrying a *Vhl^F^* allele were interbred with mice carrying a *Hif-1β^F^* allele to generate *Vhl^F/F^*; *Hif-1β^F/F^* mice. *Vhl^F/F^*; *Hif-1β^F/F^* and *Vhl^F/F^* mice were subsequently injected with Ad-Cre and efficient *loxP* site recombination was observed by PCR ([Figure 7A](#F7){ref-type="fig"}). Importantly, in the absence of *Hif-1β*, *Vhl* inactivation did not lead to hepatic steatosis or hypertriglyceridemia ([Figure 7B and C](#F7){ref-type="fig"}). Moreover, Hif-1β inactivation rescued *Vhl^F/F^* mice from death ([Figure 7D](#F7){ref-type="fig"}). These data show that Hif-1β is required for the deleterious effects of *Vhl* loss and implicates Hif in the inhibition of mitochondrial functions observed following pVhl inactivation. Together with our oxygen measurement studies, these data show that Hif activation in the liver uncoupled from oxygen sensing is sufficient to block mitochondrial respiration and cause death.

Discussion {#S8}
==========

Here, we exploited an experimental system in which acute *Vhl* disruption in mature hepatocytes caused death within days. *Vhl* inactivation blocked fatty acid oxidation causing liver steatosis and the accumulation of triglycerides in both the liver and plasma. Using liver perfusion experiments we determined that *Vhl* loss inhibited the production of glucose and ketone bodies likely explaining the reduced circulating ketone and, eventually, glucose levels, leading thereby to the death of mice. Most importantly, *Vhl* inactivation suppressed mitochondrial respiration and mice were rescued from the lethal effects of *Vhl* loss by simultaneous inactivation of *Hif-1β*.

*Vhl*-deficient livers used approximately 50% less oxygen than their wild-type counterparts indicating a profound inhibition of mitochondrial respiration. Loss of *Vhl* did not affect all mitochondrial functions however, and urea production was normal. Compellingly, the reduction in O~2~ extraction in perfused *Vhl*-deficient livers was associated with a corresponding increase of a similar magnitude in liver pO~2~ in live mice. These data show that *Vhl* loss blocks mitochondrial respiration in the liver *in vivo*. This defect likely underlies the metabolic and death phenotypes. Specifically, gluconeogenesis is strongly dependent on the TCA cycle and mitochondrial respiration ([@R4], [@R5]). Even in mice with otherwise normal gluconeogenic gene expression, impaired hepatic TCA cycle and oxidative phosphorylation disrupts gluconeogenesis ([@R4]).

To our knowledge, this is the first study to show that *Vhl* loss and constitutive Hif activation is sufficient to block oxygen utilization and mitochondrial respiration in live animals. Despite oxygen availability, its utilization was blocked by Hif. We conclude that there is no other pathway in the liver that can thwart the effects of Hif on oxygen disposition. Incidentally, the adverse effects of sustained Hif activation in the liver may explain why, even under conditions of prolonged hypoxia, Hif-1α upregulation in the liver is short-lived ([@R54]).

These results are in contrast to those from Rankin *et al.* who using isolated mitochondria from Alb-Cre; *Vhl^F/F^* livers and succinate or glutamate as substrates reported that *Vhl* loss in hepatocytes did not affect oxygen consumption ([@R51]). We speculate that the differences observed between our study and that by Rankin *et al.* arose because *in organello* measurements do not fully reproduce the fine metabolic autoregulation that occurs in the closed metabolic pathways in intact organs. Our findings highlight the importance of *ex vivo* perfusion experiments and *in vivo* oxygen measurements.

The particular roles of Hif-1α and Hif-2α in the metabolic derangement observed are unknown. Rankin and colleagues showed that inactivation of Hif-2α (but not Hif-1α) prevented steatosis in Alb-Cre; *Vhl^F/F^* livers ([@R51]). However, Kim *et al.* showed that overexpression of a constitutively active form of Hif-2α did not result in liver steatosis and that by contrast, liver steatosis was caused by a stable form of Hif-1α ([@R29]). In the studies by Kim *et al.*, the severe steatosis observed in Alb-Cre; *Vhl^F/F^* livers was most closely recapitulated by simultaneous activation of both Hif-1α and Hif-2α proteins and both Hif-1α and Hif-2α proteins may be similarly implicated in Ad-Cre *Vhl^F/F^* liver steatosis.

Extensive changes in gene expression were observed following *Vhl* inactivation and it seems unlikely that changes in a single gene would account for the profound suppression in mitochondrial respiration observed. Mitochondrial biogenesis ([@R64], [@R65]) and autophagy ([@R32], [@R65]) are regulated by Hif-1. However, since urea production was unaffected, it is improbable that the decrease in oxygen consumption observed resulted from decreased mitochondrial mass. One mechanism may involve the Fe-S cluster assembly proteins IscU1/2, which are regulated by pVhl in a miR-210-dependent manner ([@R6]), and which we found to be downregulated in Ad-Cre *Vhl^F/F^* livers. Low IscU1/2 levels have been implicated in reducing aconitase and complex I activities ([@R6]) and may also directly affect β-oxidation, which requires Fe-S cluster containing electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO). Another factor contributing to decreased mitochondrial respiration may be *Pdk1*, a Hif-1 target gene ([@R28], [@R46]) which was induced in *Vhl*-deficient livers, and which would downregulate the amount of pyruvate-derived acetyl-CoA available for the TCA cycle.

The phenotype of Ad-Cre *Vhl^F/F^* animals resembled human inborn fatty acid oxidation defects which are associated with liver steatosis and hypoketotic hypoglycemia ([@R61]). In patients, death may be precipitated by a viral illness, and in mice, death may have been hastened by the adenoviral infection. Humans with inborn errors in FAO are treated with glucose ([@R52]), and exogenous glucose administration prolonged the survival of mice. However, whereas in humans supportive treatment during an acute illness may avert death, glucose administration to mice delayed survival only by a short period of time indicating that the underlying deficit may be more severe.

The finding that *Vhl* disruption is sufficient to suppress mitochondrial respiration may be amenable to therapeutic exploitation as it would suggest that *VHL*-deficient tumors may be exquisitely dependent on glycolysis for ATP generation. While the effects of *Vhl* loss on mitochondrial respiration may be tissue-specific, a similar suppression of mitochondrial functions may also occur in ccRCC. Indeed, ccRCCs have low respiratory chain protein content ([@R53]) and impaired mitochondrial function may contribute to the accumulation of TG in this tumor type. In fact, miR-210 is one of the most upregulated microRNAs in ccRCC ([@R8], [@R22], [@R23], [@R33]) and this would be expected to downregulate IscU1/2 proteins. Thus inhibitors of glycolysis may be particularly efficacious against this tumor type.

In summary, our data show that proper Hif regulation is essential for oxygen homeostasis in the liver. Unchecked, Hif is sufficient to suppress mitochondrial respiration *in vivo* leading to impaired fatty acid oxidation and reduced ketone and glucose production ultimately causing death. Despite oxygen availability, Hif blocks oxygen utilization. Thus, no other oxygen sensing pathway exists in hepatocytes that can substantially modulate the effects of Hif.

Materials and methods {#S9}
=====================

Animals {#S10}
-------

All animal experiments were approved by IACUC. Two to six month old animals of a mixed background were used for Ad-Cre experiments. *Vhl^F^* mice ([@R16]) or intercrossed with animals bearing *Hif-1β^F^* allele ([@R57]). Adenovirus coding for Cre recombinase (Ad-Cre) was injected by tail vein, 6×10^9^ pfu/animal. Efficiency of recombination of *Vhl^F^* and *Hif-1β^F^* alleles was tested by PCR using genomic DNA and primers listed in [Table S2](#SD1){ref-type="supplementary-material"}. Albumin-Cre animals were genotyped at 14 days of age and at that point the survival study was started.

Human tissue {#S11}
------------

Clear-cell renal cell carcinoma and normal renal cortex samples flash frozen in liquid nitrogen and stored at -80°C were obtained from UT Southwestern tissue bank. Only those samples were used that were devoid of surrounding fat tissue and necrosis, and in case of carcinomas, which exhibited tumor content higher than 70% (inferred from an analysis by a pathologist from H&E of immediate flanking sections).

Glucose and WY-14643 treatment {#S12}
------------------------------

Glucose (25% in water) or equivalent volume of normal saline (0.9%, Baxter) was given by intraperitoneal injection (IP), 2 mg/g of body weight every 8 hours starting 70 hours after Ad-Cre injection and continued until the last *Vhl^F/F^* animal in the group died. WY-14643 in olive oil (5 mg/ml) or equivalent volume of vehicle was given by oral gavage at 50 mg/kg of body weight starting 24 hours before Ad-Cre injection. In the PPARα activation study, animals were given five doses every 24 hours and sacrificed 6 hours after the last gavage. In the survival study, the first four doses were given every 24 hours and then every 48 hours; last dose was given to WT animals at day 8 after Ad-Cre injection. Because compared to females, PPARα appears to be more active in males ([@R9]), males were used for the WY-14643 study.

Blood and tissue analysis {#S13}
-------------------------

Animals were anesthetized by inhalation of isofluorane (Aerrane, Baxter). Blood was collected from the left ventricle after opening the chest. To obtain plasma, blood was transferred immediately into heparin coated tubes. Plasma and serum were analyzed using Vitros 250 Chemistry System (Johnson and Johnson) except for ketone bodies, which were tested by Autokit Total Ketone Bodies (Wako). Tissues were removed immediately after blood collection and were flash-frozen in liquid nitrogen or fixed in formalin for histological analysis. ccRCC samples were treated similarly. Oil red O staining (Poly Scientific) of frozen sections was performed overnight and was followed by hematoxylin counterstaining. Tissue lipid composition analysis was performed by UT Southwestern Mouse Metabolic Phenotyping Core. Lipids were extracted from frozen tissues as previously described ([@R12]). Briefly, a piece of tissue (100--200 mg) was homogenized in 5 ml of chloroform:methanol (2:1, v/v) using a homogenizer, 1 ml of saline was added and the mixture was vortexed vigorously. The phases of the Folch extraction were separated by centrifugation at 3000 × g for 20 min, the organic phase was transferred to a 5 ml volumetric flask, and the final volume was brought up to 5 ml with chloroform. TG and cholesterol in the chloroform phase were measured using enzymatic assays (Thermo Scientific) ([@R30]).

Isolation of liver mitochondria {#S14}
-------------------------------

Crude mitochondria were isolated as previously described ([@R39]).

Western blot analysis {#S15}
---------------------

Tissue lysates were prepared using QIAshredder columns (Qiagen) as described elsewhere (Peña-Llopis *et al.*, in preparation). Antibodies were obtained from the following sources: Novus Biologicals: Glut-1; Santa Cruz: IscU1/2, pVhl, donkey anti-goat HRP-IgG; Abcam: Ppib; Thermo Scientific: Hsp70; Pierce: goat anti rabbit HRP-IgG.

Quantitative reverse transcribed real-time PCR {#S16}
----------------------------------------------

cDNA was synthesized from 2-4 μg of total RNA using random primers (Invitrogen) and M-MLV-RT (Invitrogen). PCR was run using iTag Fast SYBR Green Supermix with ROX (BioRad) or Express SYBR GreenER qPCR Supermix Universal (Invitrogen) and a 7500 Real Time PCR System (Applied Biosystems). Primers are listed in [Table S3](#SD1){ref-type="supplementary-material"}.

Liver perfusion {#S17}
---------------

Livers from animals fasted for ∼24 hours on day 4 after Ad-Cre injection were perfused without recirculation for 60 min as previously described ([@R3]) except that the perfusion media contained FFAs instead of octanoate and was supplemented with 0.1 mM glutamate, 1.0 mM glutamine, and 1.0 mM alanine. Effluent perfusate was collected for assays of glucose, ketones and urea. Glucose was measured using the hexokinase/glucose-6-phosphate dehydrogenase coupled assay ([@R2]), ketones by Autokit 3-HB (Wako) and Autokit Total Ketone Bodies (Wako), and urea by an analytical kit (BioAssay Systems, Hayward, CA). Oxygen consumption was calculated based on the difference in oxygen tension in afferent and efferent perfusate measured by a blood gas analyzer (Instrumentation Laboratory, Lexington, MA).

In vitro fatty acid oxidation {#S18}
-----------------------------

Livers from Ad-Cre injected mice on day 3 after injection were removed and immediately submerged in an ice cold reaction solution ([@R11]) buffered with 100 mM HEPES pH 7.3. Liver specimens (∼500 mg) were minced in reaction buffer and then homogenized with 8 strokes of a hand operated Potter-Elvehjem homogenizer. \[1-^14^C\]-oleate (Perkin Elmer) was added to 200 μl of homogenate to a final concentration of 50 μM and the tube was immediately inserted into a vial with silicone septa containing filter paper soaked in hyamine hydroxide at 37°C. Reactions were terminated after 5, 10, 15 and 20 minutes by injection of 100 μl of 7% perchloric acid. After 60 minutes, the filter paper with the captured ^14^CO~2~ was transferred into a vial with 4 ml of scintillation fluid and counts were measured for 1 minute. Results are expressed as μmoles of ^14^CO~2~ per minute for mg of liver.

Hepatic acylcarnitine profile {#S19}
-----------------------------

Twenty to thirty mg liver samples from fed and 24 hours fasted mice were homogenized in acetonitrile and acylcarnitines were isolated and quantified as previously described ([@R40]) with some minor modifications. An API 3200 triple quadrupole LC-MS/MS mass spectrometer (Applied Biosystems/Sciex Instruments) in positive ionization MRM mode was used to detect carnitines after LC separation. Free carnitine was monitored using the 176 to 117 MRM transition. Acylcarnitines were monitored using a precursor of 99 Da. Acylcarnitines were quantified by comparison of the individual ion peak area with that of an internal ^13^C standard (Cambridge Isotope Laboratories, Inc.).

In vivo liver pO~2~ analysis {#S20}
----------------------------

Oxypherol (perfluorotributylamine emulsion, Alpha Therapeutics Corp., FTBA, 1ml/day) was administered by IP injection to *Vhl*^+/+^ and *Vhl^F/F^* mice for 3 consecutive days starting 24 hours post Ad-Cre injection. At day 4 after Ad-Cre injection, 24 hours after the final administration of Oxypherol, NMR/MRI studies were performed on a 4.7 T Varian Unity INOVA scanner. Mice were anesthetized (isoflurane) and placed into a 3 cm diameter home-built volume coil (tunable from 188.2 MHz for ^19^F to 200.1MHz for ^1^H) that covered the torso of the animal, and was centered on the liver. Animal temperature was maintained at 36 ± 1°C by a pad with circulating warm water. Shimming and pulse calibration were performed on the tissue water proton signal and T~1~-weighted anatomical ^1^H images were acquired (acquisition parameters: FOV 50 mm × 50 mm, matrix 128 × 128, slice thickness 1 mm, TR/TE = 500 ms/12 ms). ^19^F NMR spectra were obtained after tuning the coil to ^19^F resonance frequency. Each spectrum was acquired in 8 s (acquisition parameters: pulse width 40 μs, 8 acquisitions, 60 Hz exponential line broadening) and was used to locate the most upfield resonance frequency, which is assigned to CF~3~ resonance of FTBA ([@R36]). T~1~ values of the CF~3~ resonance in liver were measured using chemical shift selective imaging with varying repetition times (acquisition parameters: FOV 50 mm × 50 mm, matrix 32 × 32, slice thickness 10 mm). Images with different repetition times were fit with the standard 3-parameter saturation recovery model using the Image Browser software on the Varian scanner to generate maps of T~1~ and ΔT~1~ (where ΔT~1~ is the standard error in T~1~ curve fit for voxel), R~1~(=1/T~1~) maps were converted to pO~2~ maps using published calibration curves R~1~ = A + (B \* pO~2~), where A = 0.684 s^-1^ and B = 0.305 × 10^-2^ (torr × s)^-1^ ([@R60]), using MATLAB software routines. Only voxels from the liver region that were consistently present on both air-breathing and oxygen-breathing T~1~ maps and had a ΔT~1~/T~1~ \< 25% were used for further analysis. Final pO~2~ value for each animal was calculated as median of pooled voxels.

Statistical analysis {#S21}
--------------------

All data are presented as means with standard deviations unless otherwise specified. *p* values are calculated by two tailed Student\'s *t* test assuming equal variances unless otherwise specified. For the survival curves a Log-rank test was used. SAS 9.1.3 Service Pack 3 XP_PRO platform was used for the analysis except the in vivo pO~2~ measurements, where Origin 6.1 software was used.
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![Albumin-Cre; *Vhl^F/F^* mice develop liver steatosis and exhibit a shortened but unpredictable survival. (**A**) Microscopic sections of representative liver areas from 3-week old animals (original magnification × 200). (**B**) Survival curves of Albumin-Cre; *Vhl*^+/+^ and Albumin-Cre; *Vhl^F/F^* animals (*n* = 50).](nihms254848f1){#F1}

![Acute *Vhl* inactivation in hepatocytes is lethal. (**A**) PCR analysis of genomic DNA isolated from tissues of *Vhl*^+/+^ and *Vhl^F/F^* animals at the indicated number of days post Ad-Cre injection; 1:1 mixture of genomic DNA containing unrecombined (*Vhl^F^*) and completely recombined (*Vhl^Frec^*) alleles was used as amplification control. (**B**) Western blot analysis of liver lysates from 24 hours fasted animals of the indicated genotypes following the stated number of days after Ad-Cre. (**C**) Survival curve of Ad-Cre injected animals of the indicated genotypes (*n* = 21).](nihms254848f2){#F2}

![Acute *Vhl* inactivation in the liver leads to hepatic steatosis reminiscent of the lipid accumulation in ccRCC. (**A**) Macroscopic images and (**B**) microscopic sections of representative liver areas (original magnification × 200) of mice fasted for 24 hours of the indicated genotypes, either untreated or 5 days after Ad-Cre injection; open arrow heads, inflammatory cells; H&E, hematoxylin eosin. (**C**) Triglyceride composition of livers from animals of the indicated genotypes, either nonfasted or fasted for 24 hours (*n* = 2-4 for each genotype and timepoint). (**D**) Circulating triglycerides from nonfasted or 24 hours fasted animals (*n* = 3-6 for each genotype and timepoint). Cholesterol levels in nonfasted animals (as in C) in liver (**E**) or serum (**F**). (**G**) Representative images of clear-cell renal cell carcinoma (ccRCC) and normal renal cortex sections stained by H&E and Oil red O with a hematoxylin counterstain (original magnification × 200). (H) Lipid composition analysis of ccRCC and normal renal cortex (*n* = 9-10 per group). \*, *p* \< 0.05; \*\*, *p* \< 0.01.](nihms254848f3){#F3}

![*Vhl* inactivation blocks hepatic ketone production leading to decreased circulating ketone levels and death which is refractory to PPARα activation. (**A**) Levels of plasma ketones (acetoacetate plus 3-hydroxybutyrate) in animals fasted for 24 hours (for both genotypes, *n* = 2 for day 0, *n* = 4-8 for other time points). (**B**) Ketone body production by perfused livers isolated from 24 hours fasted animals at day 4 post Ad-Cre injection (*n* = 6 for each genotype); TK, total ketones; BHB, β-hydroxybutyrate; ACAC, acetoacetate. (**C**) In vitro fatty acid oxidation rates measured as ^14^CO~2~ production in liver homogenates from 24 hours fasted animals at day 3 post Ad-Cre injection (*n* = 2). (**D**) qRT-PCR analysis of PPARα target genes (or controls) normalized to *Ppib* in animals of the indicated genotypes 3 days after Ad-Cre injection and following 4 days of WY-14643 (WY), olive oil (vehicle), or no treatment (NT) (for both genotypes, *n* = 4-5 for each treatment). \*, *p* value comparing *Vhl^F/F^* vs. *Vhl*^+/+^; \#, *p* value comparing WY to vehicle within the same mouse strain. (**E**) Survival curve for Ad-Cre injected animals treated with olive oil (vehicle) or WY-14643 (*n* = 5 for each genotype and treatment group). (**F**) Analysis of plasma triglycerides, same animals as in D (*n* = 3 per group). \* and \#, *p* \< 0.05; \*\* and \#\#, *p* \< 0.01.](nihms254848f4){#F4}

![Decreased hepatic glucose production with consequent hypoglycemia contributes to the death of *Vhl^F/F^* animals. (**A**) Plasma glucose levels after a 24 hour fast. (**B**) Glucose and (**C**) urea production by perfused livers from animals fasted ∼24 hours on day 4 post Ad-Cre injection (*n* = 6 for each genotype). (**D**) Survival curves of *Vhl^F/F^* animals treated with glucose (or saline) intraperitoneally at 8 hour intervals starting when indicated (*n* = 7 for each treatment). \*, *p* \< 0.05; \*\*\*, *p* \< 0.001.](nihms254848f5){#F5}

![Accumulation of short acylcarnitines and inhibition of oxygen consumption in *Vhl*-deficient livers. (**A**) Acylcarnitine levels in extracts from livers of fed or fasted animals sacrificed at day 4 after Ad-Cre injection, (*n* = 6-7 for each genotype in fed or fasted conditions; for absolute values see [Table S1](#SD1){ref-type="supplementary-material"}). (**B**) Oxygen consumption rates of perfused livers from animals fasted ∼24 hours and sacrificed on day 4 post Ad-Cre injection (*n* = 6 for each genotype). (**C**) Western blot analysis of perfused livers (as in B) or crude mitochondria (**D**) isolated from livers of fasted animals at the indicated days after Ad-Cre injection. (**E**) Liver oximetry using ^19^F MRI of Oxypherol (perfluorobutylamine emulsion) in *Vhl*^+/+^and *Vhl^F/F^* mice on day 4 post Ad-Cre injection. Representative T~1~-weighted ^1^H MRI coronal scans illustrating anatomy of mouse torso showing lung (Lu), liver (Li), stomach (St) and spleen (Sp) from a representative pair of animals. Overlay on anatomical images of pO~2~ maps (logarithmic color scale) obtained while breathing air or 100% oxygen. (**F**) Summary of *in vivo* pO~2~ measurement (*n* = 3 for each genotype). \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001, paired *t* test was used when comparing 21% *vs.* 100% O~2~.](nihms254848f6){#F6}

![Rescue of Ad-Cre *Vhl^F/F^* mice by *Hif-1β* loss. (**A**) PCR analysis of genomic DNA isolated from livers of *Vhl^F/F^* animals either *Hif-1β*^+/+^ or *Hif-1β^F/F^* at the indicated number of days post Ad-Cre injection. (**B**) H&E staining of representative liver sections from *Vhl^F/F^*; *Hif-1β*^+/+^ livers (and controls) analyzed at day 5 post Ad-Cre injection (original magnification × 200). (**C**) Plasma triglyceride levels in Ad-Cre treated animals (*n* = 3-4 for each genotype and timepoint). \*\*, *p* \< 0.01. (D) Survival curve for Ad-Cre treated animals of the indicated genotypes (*n* = 8-9 per group).](nihms254848f7){#F7}

###### 

qRT-PCR analysis of gene expression in mice of the indicated genotypes at the indicated number of days following Ad-Cre injection (*n* = 3 for genotype and timepoint). \* *p* \< 0.05, \*\* *p* \< 0.01.

                                                 Fold change *Vhl^F/F^* / *Vhl^+/+^*              
  ---------------------------------------------- ------------------------------------- ---------- -----------
  [Hif targets]{.ul}                                                                              
  Vegf                                           1.23                                  7.95\*\*   13.73\*\*
  Glut-1                                         1.09                                  2.43       6.45
  [SREBP pathway]{.ul}                                                                            
  SCAP                                           1.14                                  1.14       1.37
  Insig-1                                        1.12                                  1.3        0.76
  Insig-2a                                       0.81                                  4.93\*\*   11.56\*\*
  Insig-2b                                       1.22                                  1.07       1.86
  SREBP-1a                                       1.28                                  1.44\*     1.53
  SREBP-1c                                       1.5                                   0.83       0.04\*
  SREBP-2                                        1.2                                   1.22       1.28
  [Cholesterol synthesis]{.ul}                                                                    
  FPP Synthase                                   0.89                                  0.67       0.43
  Squalene Syntase                               1.04                                  0.68       0.32
  HMG-CoA Synthase 1                             1.1                                   0.83       0.53
  HMG-Coa Reductase                              1.59                                  0.72       0.69
  [Cholesterol degradation and transport]{.ul}                                                    
  ABCA1                                          1.13                                  2.66\*     3.83\*\*
  ABCG5                                          1.11                                  0.92       0.22\*
  CYP7A1                                         1.08                                  0.51       0.02\*
  LDL Receptor                                   1.01                                  0.76       0.44
  VLDL Receptor                                  1.96                                  3.26\*     15.07\*
  [Triglyceride synthesis]{.ul}                                                                   
  GPAT                                           0.93                                  1.55\*     1.38
  DGAT1                                          1.04                                  0.8        1.1
  DGAT2                                          1.14                                  0.9        0.28\*
  AGPAT1                                         1.13                                  1.52       1.75
  AGPAT2                                         1.0                                   1.42       0.94
  AGPAT3                                         0.94                                  1.4        2.16\*
  AGPAT4                                         0.94                                  1.71       2.06\*\*
  [Nuclear Receptors]{.ul}                                                                        
  PPARα                                          1.06                                  1.68       2.44
  PPARδ                                          1.32                                  3.15       6.23\*
  PPARγ                                          1.24                                  1.07       1.43
  LXRα                                           1.22                                  1.31       1.04
  [Fatty acid synthesis]{.ul}                                                                     
  Malic enzyme                                   1.04                                  0.59       0.73
  Acyl-CoA Synthase                              0.83                                  1.19       0.64
  Acetyl-CoA Carboxylase 1                       1.06                                  0.58       0.33\*
  Fatty Acid Synthase                            1.06                                  0.61       0.24\*
  [Fatty acid oxidation]{.ul}                                                                     
  Acyl-CoA Oxidase 1                             0.87                                  1.19       0.79
  Acetyl-CoA Carboxylase 2                       0.85                                  1.35       1.02
  Carnitine Palmitoyl Transferase 2              0.98                                  1.16       1.5

###### 

qRT-PCR analysis of gene expression in Ad-Cre injected animals, fasted for 24 hours (*n* = 4 for genotype and timepoint).\* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.

                                       Fold change *Vhl^F/F^* / *Vhl^+/+^*, fasted                
  ------------------------------------ --------------------------------------------- ------------ ------------
  [Hif targets]{.ul}                                                                              
  Glut-1                               1.18                                          2.21\*\*     4.68\*
  Pdk1                                 1.06                                          4.18\*\*\*   6.66\*\*\*
  [Nuclear Receptors]{.ul}                                                                        
  PPARα                                1.16                                          1.63\*\*\*   1.41
  RXRα                                 0.98                                          0.67\*\*     0.83
  [Fatty acid oxidation]{.ul}                                                                     
  Acyl-CoA Oxidase 1                   1.36                                          0.68\*\*     1.09
  Carnitine palmitoyl transferase 1a   1.13                                          0.45\*\*     0.37\*\*\*
  Carnitine palmitoyl transferase 2    1.03                                          1            1.33
  Mcad                                 1.34                                          1.18         1.17
  Lcad                                 1.09                                          1.04         1.51
  [Ketogenesis]{.ul}                                                                              
  HMG-CoA synthase 2                   1.33                                          0.99         1.18
  [Gluconeogenesis]{.ul}                                                                          
  Pepck                                1.14                                          0.44\*\*     0.49
  G6Pase                               0.96                                          0.72         1.2
  PGC-1α                               0.91                                          0.45\*       0.5
  [Lipid droplet proteins]{.ul}                                                                   
  Adfp                                 1.05                                          1.22         1.71
